Device and method for delivery of combination nasal medication

• US 20060207596A1
• Filed: 09/30/2005
• Published: 09/21/2006
• Est. Priority Date: 03/18/2005
• Status: Abandoned Application

• Current Assignee: Fairfield Clinical Trials, LLC
• Original Assignee: Fairfield Clinical Trials, LLC
• Inventors: Lane, Edward M.
• Application Number:
  US11/239,348
• Publication Number:
  US 20060207596A1
• Time in Patent Office: Days
• US Class Current: 128/206.110
• CPC Class Codes: A61M 11/00 Sprayers or atomisers specially adapted for therapeutic purposes in general B05B; aerosol containers B65D83/14
• CPC Class Codes: A61M 11/007 Syringe-type or piston-type sprayers or atomisers
• CPC Class Codes: A61M 15/0003 with means for dispensing more than one drug
• CPC Class Codes: A61M 15/08 Inhaling devices inserted into the nose

Abstract

The present invention relates to dual nasal spray applicator devices and systems for administration of two nasal compositions in one spray or aerosol dose without mixing of the compositions prior to administration and methods of treatment using these devices and systems. The devices allow incompatible drug or other compositions to be stored and administered by a single device in a single dose, remaining separated until just prior to or during administration of the medications.

Claims

1. A dual nasal applicator system for simultaneously delivering a first nasal drug composition and a second nasal drug composition housed separately in first and second nasal composition chambers, respectively, comprising:

a spray head device comprising a nasal insertion portion having a body member and first and second openings extending through said body member, and an actuation portion that is integral with said nasal insertion portion for delivering the first and second nasal drug compositions through said first and second openings, respectively, when actuated;

a first connecting collar device having a first lower connecting portion and a first upper connecting portion, said first lower connecting portion being sealably attached to the first composition chamber and said first upper connecting portion being attached to said spray head device;

a second connecting collar device having a second lower connecting portion and a second upper connecting portion, said second lower connecting portion being sealably attached to the second composition chamber and said second upper connecting portion being attached to said spray head device;

a dual dispenser system having a first metered dispenser device and a second metered dispenser device;

said first dispenser device comprises a first lower portion member extending through and beneath said first connecting collar device to form a first liquid conduit from the first composition chamber, and a first upper portion member communicable with said first lower portion member for delivering a metered volume of the first nasal drug composition housed in the first composition chamber to said first opening of said spray head; and

said second dispenser device comprises a second lower portion member extending through and beneath said second connecting collar device to form a second liquid conduit from the second composition chamber, and a second upper portion member communicable with said second lower portion member for delivering a metered volume of the second nasal drug composition housed in the second composition chamber to said second opening of said spray head,

wherein the first and second nasal drug compositions remain separated until dispensed into a user'"'"'s nares.

2. The system of claim 1, wherein said spray head device has at least one of an oblong shape, circular shape, square shape, rectangular shape, and octagonal shape, and is configured in different widths and heights.

3. The system of claim 1, wherein said first nasal composition and said second nasal composition are dispensed in equal volumes.

4. The system of claim 1, wherein said first nasal composition and said second nasal composition are dispensed in unequal volumes.

5. The system of claim 1, wherein said first nasal composition is an antihistamine drug composition and said second nasal composition is a nasal steroid drug composition.

6. The system of claim 5, wherein said antihistamine drug composition comprises an antihistamine drug selected from the group consisting of loratadine, desloratidine, terfenidine, fexofenadine, cetirizine, azelatine, azatadine, clemastine, brompheniramine, chlorpheniramine, dexbrompheniramine, diphenhydramine, doxylamine, phenindamine, pheniramine, pyrilamine, triprolidine, levocabastine, acrivastine, carbmoxamine, dexchlorpheniramine, promethazine, trimeprazine, methdilazine, hydroxyzine, rocastine, tripelennamine, meclizine, tripolidine, cyproheptadine, methscopolamine and phenylpropanolamine.

7. The system of claim 5, wherein said nasal steroid drug composition comprises a nasal steroid drug selected from the group consisting of fluticasone, dexamethasone, flunisolide, budesonide, triamcinolone and beclomethasone.